Status:
COMPLETED
Special Investigation of COMIRNATY in the Population With Underlying Diseases
Lead Sponsor:
Pfizer
Conditions:
COVID-19
Eligibility:
All Genders
12+ years
Brief Summary
Post-marketing study, Cohort study of COMIRNATY vaccines. To collect information on adverse events and COVID-19 observed after vaccination with COMIRNATY and to assess safety in patients with underlyi...
Detailed Description
This is a multicenter cohort study to be conducted in individuals with underlying diseases considered to be at high risk of aggravation of COVID-19 who are vaccinated with this product, and the invest...
Eligibility Criteria
Inclusion
- Subjects who are able to understand the content of this study and to record their symptoms in the health observation diary, and who have provided written consent to participate in this survey by themselves (or parents or legal guardians in the case of minors)
Exclusion
- There are no exclusion criteria for this study.
Key Trial Info
Start Date :
May 26 2021
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
April 14 2022
Estimated Enrollment :
1075 Patients enrolled
Trial Details
Trial ID
NCT04880447
Start Date
May 26 2021
End Date
April 14 2022
Last Update
June 21 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Pfizer Local County
Tokyo, Japan, 1518589